40 Manning Road
386 articles with Bruker Corporation
In his new role, Dr. Busse will have expanded responsibilities and oversight over the BioSpin Group, one of three key Scientific Instruments groups at the Company.
Bruker announced the release of its new Contour LS-K 3D optical profiler with LightSpeed™ focus variation technology.
Bruker announces the launch of the new INVENIO™ Fourier Transform Infrared (FT-IR) research spectrometer.
Bruker today announced that it has appointed Gerald N. Herman to serve as the Company's Interim Chief Financial Officer (CFO), effective as of March 17, 2018.
Bruker and Evosep Announce New Integrated Clinical Research Proteomics Solution to Quantify Over a Thousand Proteins in Five Minutes
Bruker and Evosep announce that they have executed a co-development and co-marketing agreement for the Evosep One chromatography system to work seamlessly with Bruker's timsTOF Pro ultra-high resolution quadrupole time of flight mass spectrometer.
Bruker Names Burkhard Prause, President of Bruker Energy & Supercon Technologies (BEST), an Executive Officer of Bruker Corporation
Dr. Prause has a successful track record of leading BEST through a significant expansion of its business in the last decade, with a focus on customer needs, productivity, quality and innovation.
Will highlight various innovative analytical systems and new high-value solutions for food analysis, pharmaceutical, clinical research, and materials science applications.
Bruker Corporation announced that Mr. Anthony L. Mattacchione, Chief Financial Officer (CFO) and Senior Vice President of Bruker, has submitted his resignation, effective as of March 16, 2018.
The Bruker MALDI Biotyper Solution Receives AOAC International Approvals for Two Official Methods of Analysis (OMA) in Food Microbiology
Bruker is pleased to announce that AOAC International has approved the MALDI Biotyper solution for two new Official Methods of Analysis for the confirmation and identification of pathogenic and non-pathogenic bacteria.
Bruker today announced financial results for its fourth quarter and fiscal year ended December 31, 2017.
Bruker today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.04 per share on the Company's common stock.
Bruker's revenues for the third quarter of 2017 were $435.6M, an increase of 10.6% compared to the third quarter of 2016.
Bruker Corporation Introduces Additional Key Products For Diagnosis And Susceptibility Testing Of Invasive Fungal Diseases (IFD) Into European Clinical Microbiology Markets
Bruker Corporation Announces Acquisition Of MERLIN To Add Selected Antibiotic Resistance And Susceptibility Testing To Its MALDI Biotyper Microbial Identification Platform
Bruker Corporation Launches The timsTOF Pro Mass Spectrometer To Enable The Revolutionary PASEF Method For Next-Generation Proteomics
Bruker Corporation Announces Novel D8 Venture Biotools For Advanced Structural Biology Research By X-Ray Crystallography
Hungarian Ministry Of Agriculture Selects Bruker Corporation NMR FoodScreener For Authentication And Identification Of Hungarian Wines
Bruker Corporation Announces Acquisition Of Field-Portable Platform For Fast And Universal Immunoassay-Detection Of Bacteria, Viruses And Toxins